These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9916613)

  • 21. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
    Ho BC; Miller D; Nopoulos P; Andreasen NC
    J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Jerrell JM
    Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
    Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
    Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
    de Haan L; Beuk N; Hoogenboom B; Dingemans P; Linszen D
    J Clin Psychiatry; 2002 Feb; 63(2):104-7. PubMed ID: 11874209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
    Revicki DA
    Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 32. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D; Moisan J; Abdous B; Grégoire JP
    Can J Clin Pharmacol; 2008; 15(3):e385-97. PubMed ID: 18953083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
    Liu CY; Chiu NY; Wu CK; Yuan LM; Hsiao MC; Liao O
    Int Clin Psychopharmacol; 2003 Jan; 18(1):49-51. PubMed ID: 12490775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
    Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD
    J Clin Psychopharmacol; 1997 Oct; 17(5):407-18. PubMed ID: 9315992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals.
    Voris JC; Glazer WM
    Psychiatr Serv; 1999 Feb; 50(2):163-4, 168. PubMed ID: 10030472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.